NBIX Neurocrine Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: NBIX
Price (delayed)
$131.62
Market cap
$13.05B
P/E Ratio
37.82
Dividend/share
N/A
EPS
$3.48
Enterprise value
$13.23B
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological
Highlights
The gross profit has grown by 19% YoY and by 4% from the previous quarter
Neurocrine Biosciences's revenue has increased by 18% YoY and by 4% QoQ
The price to earnings (P/E) is 61% lower than the 5-year quarterly average of 96.3 but 6% higher than the last 4 quarters average of 35.7
Neurocrine Biosciences's quick ratio has decreased by 24% YoY but it has increased by 3.2% from the previous quarter
The debt has soared by 71% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.neurocrine.com/
Key stats
What are the main financial stats of NBIX
Market
Valuations
Earnings
Shares outstanding
99.18M
Market cap
$13.05B
Enterprise value
$13.23B
Price to earnings (P/E)
37.82
Price to book (P/B)
4.83
Price to sales (P/S)
5.19
EV/EBIT
25.1
EV/EBITDA
23.21
EV/Sales
5.27
Revenue
$2.51B
Gross profit
$2.47B
Operating income
$495M
Net income
$348.3M
EBIT
$527.1M
EBITDA
$569.9M
Free cash flow
$528.7M
Per share
Balance sheet
Liquidity
EPS
$3.48
EPS diluted
$3.38
Free cash flow per share
$5.34
Book value per share
$27.22
Revenue per share
$25.35
TBVPS
$38.92
Total assets
$3.89B
Total liabilities
$1.2B
Debt
$439.1M
Equity
$2.69B
Working capital
$1.2B
Debt to equity
0.16
Current ratio
3.2
Quick ratio
2.88
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
22.7%
Gross margin
98.5%
Net margin
13.9%
Operating margin
19.7%
Return on assets
9.4%
Return on equity
13.2%
Return on invested capital
15.9%
Return on capital employed
15.8%
Return on sales
21%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NBIX stock price
How has the Neurocrine Biosciences stock price performed over time
Intraday
2.12%
1 week
2.48%
1 month
-1.38%
1 year
-12.66%
YTD
-3.58%
QTD
4.72%
Financial performance
How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$2.51B
Gross profit
$2.47B
Operating income
$495M
Net income
$348.3M
Gross margin
98.5%
Net margin
13.9%
The operating margin has contracted by 22% YoY and by 3.9% from the previous quarter
The gross profit has grown by 19% YoY and by 4% from the previous quarter
Neurocrine Biosciences's revenue has increased by 18% YoY and by 4% QoQ
The company's net income rose by 14% QoQ and by 2.7% YoY
Price vs fundamentals
How does NBIX's price correlate with its fundamentals
Growth
What is Neurocrine Biosciences's growth rate over time
Valuation
What is Neurocrine Biosciences stock price valuation
P/E
37.82
P/B
4.83
P/S
5.19
EV/EBIT
25.1
EV/EBITDA
23.21
EV/Sales
5.27
The price to earnings (P/E) is 61% lower than the 5-year quarterly average of 96.3 but 6% higher than the last 4 quarters average of 35.7
NBIX's EPS is up by 15% since the previous quarter
NBIX's price to book (P/B) is 22% lower than its 5-year quarterly average of 6.2 but 5% higher than its last 4 quarters average of 4.6
The company's equity rose by 7% YoY and by 6% QoQ
The stock's price to sales (P/S) is 25% less than its 5-year quarterly average of 6.9
Neurocrine Biosciences's revenue has increased by 18% YoY and by 4% QoQ
Efficiency
How efficient is Neurocrine Biosciences business performance
The ROE has grown by 12% from the previous quarter but it has contracted by 11% YoY
Neurocrine Biosciences's return on assets has decreased by 10% YoY but it has increased by 9% QoQ
The company's return on invested capital rose by 9% QoQ but it fell by 5% YoY
NBIX's return on sales is up by 9% since the previous quarter
Dividends
What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NBIX.
Financial health
How did Neurocrine Biosciences financials performed over time
The total liabilities has soared by 50% YoY and by 3.8% from the previous quarter
The company's current ratio fell by 24% YoY but it rose by 2.2% QoQ
The debt is 84% lower than the equity
The debt has soared by 71% YoY
NBIX's debt to equity has surged by 60% year-on-year but it is down by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.